| [1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40.
|
| [3] |
Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer[J]. Tumor Biol, 2017, 39(7): 1010428317714626.
|
| [4] |
Yazici O, Sendur MA, Ozdemir N, et al. Targeted therapies in gastric cancer and future perspectives[J]. World J Gastroenterol, 2016, 22(2): 471-489.
|
| [5] |
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018, 359(6382): 1350-1355.
|
| [6] |
Sun L, Zhang L, Yu J, et al. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: A systematic review and Meta-analysis[J]. Sci Rep, 2020, 10(1): 2083.
|
| [7] |
Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial[J]. Lancet Oncol, 2016, 17(6): 717-726.
|
| [8] |
Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111): 2461-2471.
|
| [9] |
Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014, 513: 202-209.
|
| [10] |
Derks S, de Klerk LK, Xu X, et al. Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas[J]. Ann Oncol, 2020, 31(8): 1011-1020.
|
| [11] |
Xie J, Fu L, Jin L. Immunotherapy of gastric cancer: past, future perspective and challenges[J]. Pathol Res Pract, 2021, 218: 153322.
|
| [12] |
祁玲，黄镜. PD-1/PD-L1抑制剂在晚期胃癌治疗中的临床研究进展[J]. 中国生化药物杂志, 2016, 36(7): 4-7.
|
| [13] |
National Cancer Institute. Immune checkpoint inhibitors[EB/OL].
URL
|
| [14] |
Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580.
|
| [15] |
Shitara K, özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2018, 392(10142): 123-133.
|
| [16] |
Chen T, Satoh T, Ryu MH, et al. A phase Ⅲ study of Nivolumab (NIVO) in previously treated advanced gastric or gastricesophageal junction (G/GEJ) cancer (ATTRACTION-02): 2-year update data[J]. Gastr Cancer, 2019, 23(3): 510-519.
|
| [17] |
Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: chemotherapy with immunogenic cell death inducers[J]. Oncoimmunology, 2014, 3(1): e27878.
|
| [18] |
Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial[J]. JAMA Oncol, 2018, 4(5): e180013.
|
| [19] |
Xu J, Jiang H, Pan Y, et al. LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase Ⅲ study[J]. Ann Oncol, 2021, 32: S1331.
|
| [20] |
Corraliza-Gorjón I, Somovilla-Crespo B, Santamaria S, et al. New strategies using antibody combinations to increase cancer treatment effectiveness[J]. Front Immunol, 2017, 8: 1804.
|
| [21] |
Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J]. Nature, 2021, 600(7890): 727-730.
|
| [22] |
Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma[J]. Future Oncol, 2021, 17(10): 1155-1164.
|
| [23] |
Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 255.
|
| [24] |
Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer[J]. J Clin Oncol, 2018, 36(28): 2836-2844.
|
| [25] |
Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway[J]. PLoS One, 2019, 14(2): e0212513.
|
| [26] |
Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: An open-label, dose-escalation, and dose-expansion phase Ⅰb trial (REGONIVO, EPOC1603)[J]. J Clin Oncol, 2020, 38(18): 2053-2061.
|
| [27] |
Kawazoe A, Fukuoka S, Nakamura Y, et al. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): An open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(8): 1057-1065.
|
| [28] |
Tang C, Wang X, Soh H. et al. Combining radiation and immunotherapy: A new systemic therapy for solid tumors?[J]. Cancer Immunol Res, 2014, 2(9): 831-838.
|
| [29] |
Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Clinical Trial Nat Med, 2022, 28(6): 1189-1198.
|
| [30] |
Wall JA, Klempner SJ, Arend RC. The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer[J]. Expert Opin Investig Drugs, 2020, 29(7): 639-644.
|
| [31] |
Yanai H, Ban T, Wang Z, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses[J]. Nature, 2009, 462(7269): 99-103.
|
| [32] |
Le DT, Uram JN, Wang H. et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Eng J Med, 2015, 372(26): 2509-2520.
|
| [33] |
Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 cinical KEYNOTE-059 trial[J]. JAMA Oncol, 2018, 4(5): e180013.
|
| [34] |
Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371): 91-97.
|
| [35] |
Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer[J]. CA Cancer J Clin, 2021, 71(3): 264-279.
|
| [36] |
Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial[J]. Lancet Oncol, 2020, 21(1): 121-133.
|